Kyowa Kirin is committed to developing rokazumab as an innovative drug with significant market potential for the treatment of moderate to severe atopic dermatitis. The company plans to submit regulatory applications by the first half of 2026. Kyowa Kirin has terminated its collaboration with Amgen on rokazumab, taking full control of the project. Results from phase 3 studies on over 1,500 adult patients with atopic dermatitis showed promising outcomes. Rokazumab targets the OX40 receptor on T cells and has shown potential for long-term disease control. Future plans include global regulatory submissions starting in the US and expanding to other markets.

Rokazumab, a monoclonal antibody targeting OX40, offers a new treatment approach for moderate to severe atopic dermatitis by rebalancing T cells. Developed by Kyowa Kirin, the drug has shown positive results in phase 3 studies for patients with few treatment options left. The drug is also being studied for conditions like severe asthma, nodular prurigo, and other inflammatory disorders. Kyowa Kirin’s deep expertise in immunology and antibody engineering drives the progress of rokazumab, focusing on addressing the root causes of chronic inflammatory diseases. The company’s commitment to developing innovative therapies aims to meet critical unmet medical needs for patients.

Kyowa Kirin’s dedication to life-changing therapies is evident in the development of rokazumab for atopic dermatitis. The company’s rich history in pharmaceuticals spans over 70 years, with a focus on next-generation antibodies and cell and gene therapies. Rokazumab’s potential to provide valuable treatment options for atopic dermatitis patients across various clinical scenarios is key to Kyowa Kirin’s strategic focus. The drug’s promising risk-benefit profile in phase 3 trials involving over 3,300 patients emphasizes its potential as a meaningful and long-lasting treatment option for those in need.

Read more at Kyowa Kirin is dedicated to developing its drug, rokatemab, as an innovative treatment with significant market potential for patients with moderate to severe atopic dermatitis. Rokatemab is an experimental T cell rebalancing therapy that targets the OX40 receptor on pathogenic T cells, offering potential long-term disease control for patients. The company plans to submit a regulatory application in the first half of 2026. The news was reported by GlobeNewswire.: Kyowa Kirin